Australia is carefully awaiting the arrival of retatrutide, a novel dual GIP and GLP-1 receptor agonist that's generating significant buzz in the global weight management landscape. Developed by Novo Nordisk, this https://diegolmnh861599.bloguerosa.com/41390217/retatrutide-australia-a-potential-breakthrough-for-obesity-treatment